Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Moodys
McKinsey
Harvard Business School
Medtronic
Baxter
Express Scripts

Last Updated: June 28, 2022

CLINICAL TRIALS PROFILE FOR OXERVATE


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for OXERVATE

Trial ID Title Status Sponsor Phase Start Date Summary
NCT04485546 ↗ Study to Evaluate OXERVATE™ in Patients With Stage 1 Neurotrophic Keratitis Recruiting Dompé US Phase 4 2020-09-09 This study is to evaluate the safety and efficacy of OXERVATE™ 0.002% (20 mcg/mL) cenegermin-bkbj ophthalmic solution in patients with Stage 1 neurotrophic keratitis (NK).
NCT04485546 ↗ Study to Evaluate OXERVATE™ in Patients With Stage 1 Neurotrophic Keratitis Recruiting Dompé Farmaceutici S.p.A Phase 4 2020-09-09 This study is to evaluate the safety and efficacy of OXERVATE™ 0.002% (20 mcg/mL) cenegermin-bkbj ophthalmic solution in patients with Stage 1 neurotrophic keratitis (NK).
NCT05133180 ↗ Study to Evaluate Safety and Efficacy of Oxervate® Ophthalmic Solution vs Vehicle in Severe Sjogren's Dry Eye Disease Not yet recruiting Dompé Farmaceutici S.p.A Phase 3 2021-11-30 The study objective is to assess the efficacy and safety of cenegermin (rhNGF) ophthalmic solution at 20 mcg/mL concentration administered three times daily for 4 weeks in patients with severe Sjogren's dry eye disease.
NCT05136170 ↗ Study to Evaluate Safety and Efficacy of Cenegermin (Oxervate®) 20 mcg/mL vs Vehicle, in Patients With Sjogren's Dry Eye Not yet recruiting Dompé Farmaceutici S.p.A Phase 3 2021-12-01 The study objective is to assess the efficacy and safety of cenegermin (rhNGF) ophthalmic solution at 20 mcg/mL concentration administered three times daily for 4 weeks in patients with severe Sjogren's dry eye disease (DED) who are under chronic treatment with topical Cyclosporine A (CsA).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for OXERVATE

Condition Name

Condition Name for OXERVATE
Intervention Trials
Neurotrophic Keratitis 1
Dry Eye 1
Dry Eye Syndrome 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for OXERVATE
Intervention Trials
Keratoconjunctivitis Sicca 2
Dry Eye Syndromes 2
Keratitis 1
Eye Diseases 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for OXERVATE

Trials by Country

Trials by Country for OXERVATE
Location Trials
United States 16
Italy 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for OXERVATE
Location Trials
California 3
Massachusetts 3
Tennessee 2
Maryland 2
Kentucky 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for OXERVATE

Clinical Trial Phase

Clinical Trial Phase for OXERVATE
Clinical Trial Phase Trials
Phase 4 1
Phase 3 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for OXERVATE
Clinical Trial Phase Trials
Not yet recruiting 2
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for OXERVATE

Sponsor Name

Sponsor Name for OXERVATE
Sponsor Trials
Dompé Farmaceutici S.p.A 3
Dompé US 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for OXERVATE
Sponsor Trials
Industry 3
Other 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Moodys
Medtronic
AstraZeneca
McKesson
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.